News + Resources
Keep up with the latest
Featured
Recent
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
All Stories
News
Deals In Depth: September 2022
October 18, 2022
Citeline In Vivo
Read Now
Press
Deals In Depth: September 2022
October 18, 2022
Citeline In Vivo
Read Now
News
Scribe Therapeutics to Participate in Upcoming Investor Conferences
September 29, 2022
Read Now
Press
Scribe Therapeutics to Participate in Upcoming Investor Conferences
September 29, 2022
Read Now
News
Follow the Money
September 28, 2022
Bio IT World
Read Now
Press
Follow the Money
September 28, 2022
Bio IT World
Read Now
News
Scribe and Sanofi partner to develop cell therapies for cancer
September 28, 2022
Pharmaceutical Technology
Read Now
Press
Scribe and Sanofi partner to develop cell therapies for cancer
September 28, 2022
Pharmaceutical Technology
Read Now